<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062408</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-ANT- 2021-01</org_study_id>
    <nct_id>NCT05062408</nct_id>
  </id_info>
  <brief_title>Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals</brief_title>
  <acronym>Hepatitis</acronym>
  <official_title>Impact of the Sustained Viral Response on the Natural History Chronic Hepatitis c After Treatment With Direct Action Antivirals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the evolution of liver injury with fibrosis data&#xD;
      obtained using non-invasive serological markers in patients who achieved SVR after treatment&#xD;
      with direct-acting antivirals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open study includes patients with chronic hepatitis C who received treatment with the&#xD;
      new direct-acting antivirals between November 1, 2014 and December 31, 2017, who achieved a&#xD;
      sustained viral response at week 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with a progression of liver injury.</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>To assess the evolution of liver injury with fibrosis data in patients who achieved SVR after treatment with direct-acting antivirals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify patients who develop liver-related events (liver decompensation, hepatocellular carcinoma, and death) after achieving sustained viral response.</measure>
    <time_frame>Up to 4 weeks.</time_frame>
    <description>Development of hepatic decompensation, defined as a patient with ascites, spontaneous bacterial peritonitis (PBR), digestive bleeding of varicose origin, or hepatic encephalopathy at some point in the evolution from SVR until the end of study follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of risk factors presented by patients.</measure>
    <time_frame>Up to 4 weeks.</time_frame>
    <description>Identify risk factors in patients who develop liver complications after achieving sustained viral response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of improvement in non-invasive fibrosis parameters vs the development of liver complications.</measure>
    <time_frame>Up to 4 weeks.</time_frame>
    <description>To determine if there is a relationship between the absence of improvement in non-invasive fibrosis parameters and the development of liver complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and fibrosis data.</measure>
    <time_frame>Up to 4 weeks.</time_frame>
    <description>To compare the clinical and fibrosis data between patients who develop liver complications and those who do not.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">321</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>cases</arm_group_label>
    <description>Patients treated with direct-acting antivirals.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population are patients with chronic hepatitis C who have been treated with&#xD;
        direct-acting antivirals between 2014 and 2017. Also patients with fibrosis and liver&#xD;
        cirrhosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic liver disease caused by virus C.&#xD;
&#xD;
          -  Have received treatment with the new DAAs between November 1, 2014 and December 1,&#xD;
             2017.&#xD;
&#xD;
          -  Patients diagnosed with advanced fibrosis and liver cirrhosis. Advanced fibrosis was&#xD;
             defined as a Fibroscan&gt; 10 kPa, an APRI index&gt; 1.5 and / or a FIB-4 index&gt; 3.25. For&#xD;
             its part, cirrhosis was defined such as a Fibroscan&gt; 12.5 kPa and / or presence of&#xD;
             esophagogastric varices in the endoscopic study and / or data portal hypertension&#xD;
             ultrasound.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coinfection by virus B or HIV.&#xD;
&#xD;
          -  Development of HCC before or during treatment.&#xD;
&#xD;
          -  Abuse of alcohol intake or addiction to parenteral drugs.&#xD;
&#xD;
          -  Liver disease of non-viral etiology (autoimmune, toxic, metabolic).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Fernández Álvarez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

